Search Bar & Filters
Found 48 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma NHL, affecting many patients with rapid tumor growth and symptoms depending on tumor location. This observational study aims to understand the clinical characteristics, treatment patterns, and access to new therapies for patients with DLBCL in the Middle East and Africa region, including both newly diagnosed and relapsed or refractory cases. Participants are grouped into two cohorts those who are newly diagnosed and eligible for treatment, and those who have relapsed or are refractory after at least one prior therapy. The study does not involve experimental treatments but collects information on how patients are treated in real-world settings and explores access to innovative therapies. During the study, patient demographics, disease characteristics, risk profiles, and treatment patterns are documented over 22 months. Researchers will gather data through reviews of medical records and clinical information without administering treatments. The primary goal is to describe first-line and subsequent treatment approaches and to understand patient access to novel therapies for DLBCL.
Actively Recruiting
Researchers are evaluating how long participants with moderate to severe Crohns disease CD or ulcerative colitis UC continue their treatment with guselkumab without stopping in a real-world setting. CD and UC are inflammatory bowel diseases affecting the colon and small intestine. The study is observational and aims to understand treatment persistence and effectiveness in routine clinical practice. Participants with confirmed moderate-to-severe UC or CD who are prescribed guselkumab by their doctors will be enrolled. No study drug is provided by the trial instead, data will be collected from the participants routine clinical care and therapeutic procedures. The study will observe treatment use and outcomes over up to 96 weeks, including responses measured at various time points and clinical assessments. During the study, participants medical records and clinical data will be reviewed to track treatment persistence and outcomes such as clinical responses, remission status, quality of life, inflammatory markers, and safety events. Data will be collected at baseline and multiple follow-up visits up to week 96. This includes monitoring disease activity, medication use, adverse events, and hospital visits to provide a comprehensive understanding of guselkumab use in real-world practice.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.
Actively Recruiting
Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.
Actively Recruiting
Researchers are studying adults aged 18 and older with warm autoimmune hemolytic anemia wAIHA, a condition where the immune system destroys red blood cells. This Phase 3 trial evaluates the effects, safety, and how the body processes rilzabrutinib compared with a placebo. The goal is to see if rilzabrutinib can increase hemoglobin levels sustainably in participants who have had the disease for at least six months and have not responded well to corticosteroid treatments. Participants will be randomly assigned in a 21 ratio to receive either oral rilzabrutinib or a placebo twice daily during the primary analysis period lasting up to 24 weeks. Those who complete this period can enter an open-label phase lasting 28 weeks where all receive rilzabrutinib. Participants who show improved hemoglobin levels near the end of this phase may continue in a long-term extension that lasts up to 52 weeks from the start of the extension. The study includes a safety follow-up of two weeks after treatment completion or discontinuation. Throughout the study, participants will have multiple visits for assessments including blood tests to measure hemoglobin changes, fatigue levels, and lung function, among others. Researchers will monitor for side effects, vital signs, and laboratory values up to 104 weeks. The primary outcome is the proportion of participants achieving a durable hemoglobin response between weeks 12 and 24. Secondary outcomes include overall hemoglobin response, fatigue improvement, and safety events. The total study duration for participants may extend up to several years depending on eligibility for the long-term extension.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Pressure injuries are a common and preventable problem among critically ill patients, especially those in intensive care units ICUs due to immobility and complex medical needs. This trial is studying whether an artificial intelligence AI-assisted skin assessment tool can improve the accuracy of pressure injury staging by critical-care nurses and whether it can increase nurses knowledge and confidence in skin assessment. Researchers aim to compare AI-assisted assessments with standard manual assessments to support earlier and more accurate detection of pressure injuries. The trial involves two groups of nurses one using a ChatGPT-based AI mobile application to assist with skin assessment and staging, and the other using traditional visual and physical examination methods. All nurses receive education on pressure injury prevention and staging, with the AI group receiving additional training on capturing standardized photos. A blinded wound-care specialist will review all assessments and images to serve as the reference for accuracy. Participants will complete questionnaires about their knowledge and confidence before and after training. Nurses will perform skin assessments on ICU patients using their assigned method, with results compared to expert evaluations. The study will measure agreement between nurse and expert staging over six months, track changes in nurses knowledge and confidence, and assess how feasible and acceptable it is to use the AI tool in ICU care workflows.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how an art-based pain assessment tool, called Artistic Pain Exploration APE, may improve communication and understanding of pain in adults with early-stage Temporomandibular Disorders TMD. This randomized controlled trial compares standard care alone to standard care combined with the APE method, aiming to see if the art tool better helps patients express their pain, improves jaw joint function, and reduces anxiety. The study is conducted by King Abdulaziz University Dental Hospital and includes adult patients with TMD who do not require surgery. Participants are assigned randomly to either receive routine diagnostic and therapeutic procedures or the same care plus the APE method. The standard care includes clinical exams, pain and anxiety assessments, depression screening, and conservative treatment with medications and lifestyle guidance. The APE method involves showing participants three paintings and guiding a discussion about how the selected image relates to their physical and emotional pain and daily life impact. The study lasts two weeks, with assessments before and after this period. During the study, all participants complete questionnaires measuring anxiety, depression, pain level, and jaw function at baseline and follow-up. Researchers monitor pain understanding, communication, and joint function using patient-reported outcomes and standardized tools. Emotional discomfort or mild anxiety may occur during discussions, and psychiatric support is available if needed. There are no costs to participate, and confidentiality is maintained throughout the study.
1-10 of 48
1